DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Insider Buying Monitor — SEC Form 4
LILA $107M
HOOD $55M
NCLH $25M
IFF $20M
and 16 more stocks
LILA $107M, HOOD $55M, NCLH $25M, IFF $20M and more: the 20 largest insider purchases of the last two weeks
From May 27 to June 11, 2026, managers, CEOs and significant shareholders bought more than $460 million worth of stock. Cash purchases only — no zero-dollar option exercises.
Insider Buying Monitor — Form 4 SEC
LILA $107M
HOOD $55M
NCLH $25M
IFF $20M
ed altri 16 titoli
LILA $107M, HOOD $55M, NCLH $25M, IFF $20M ed altri: i 20 maggiori acquisti insider delle ultime due settimane
Dal 27 maggio all’11 giugno 2026, manager, CEO e azionisti significativi hanno acquistato azioni in borsa per oltre $460 milioni. Solo acquisti in contanti — nessuna opzione a zero dollari.
Total capital
$462M+
across the top 20 purchases
Stocks covered
20
across multiple sectors
Largest purchase
$107M
LILA — John C. Malone
Period
15 days
May 27 — June 11, 2026
Capitale totale
$462M+
nei top 20 acquisti
Titoli coinvolti
20
settori diversi
Acquisto piu’ grande
$107M
LILA — John C. Malone
Periodo
15 gg
27 mag — 11 giu 2026
Quando chi comanda apre il portafoglio
Gli acquisti insider — quelli in contanti, a prezzi di mercato, da parte di chi conosce l’azienda dall’interno — sono tra i segnali piu’ seguiti dagli investitori professionali. Non sono una garanzia, ma quando un CEO, un direttore o un azionista al 10% acquista per milioni di dollari con i propri soldi, qualcosa vale la pena guardare.
Nelle ultime due settimane (27 maggio – 11 giugno 2026), abbiamo registrato 20 acquisti rilevanti con un valore complessivo che supera i 462 milioni di dollari. L’analisi esclude tutte le opzioni esercitate a prezzo zero o simbolico: si tratta esclusivamente di acquisti in mercato aperto o in offerte dirette, pagati ai prezzi correnti di borsa. I dati provengono dai Form 4 depositati presso la SEC (Securities and Exchange Commission).
Il segnale piu’ forte? John C. Malone che investe 107 milioni di dollari in Liberty Latin America quasi raddoppiando la sua quota. Un secondo segnale notevole: Meyer Malka che acquista Robinhood per $55 milioni in tre tranche separate. Poi Norwegian Cruise Line, IFF, due biotech (Artiva e Q32 Bio), una societa’ di quantum computing (Quantinuum) e molti altri. Di seguito la lista completa con i profili chiave.
Nota metodologica: il report esclude SVRE (Saverone 2014 Ltd.) — il valore registrato di $2,147,483,647 corrisponde al massimo intero a 32 bit e rappresenta un errore di overflow nel database sorgente, non un acquisto reale. Tutti gli altri dati sono coerenti con i filing SEC originali.
La tabella completa — Top 20 acquisti
Dati aggiornati all’11 giugno 2026. Ordinati per valore totale di acquisto decrescente. Acquisti multipli dello stesso insider sullo stesso titolo sono consolidati.
| # | Ticker | Azienda | Insider | Ruolo | Trade date | Prezzo medio | Valore totale | Delta % |
|---|---|---|---|---|---|---|---|---|
| 1 | LILA | Liberty Latin America Ltd. | John C. Malone | Director Emeritus | 22 mag 2026 | $8.63 | +$107,067,776 | +96% |
| 2 | HOOD | Robinhood Markets, Inc. | Malka Meyer | Dir | 28 mag — 5 giu | ~$81.50 | +$55,306,259 | +3% |
| 3 | LFTO | Liftoff Mobile, Inc. | General Atlantic | Dir, 10% | 5 giu 2026 | $23.00 | +$29,999,981 | +5% |
| 4 | NCLH | Norwegian Cruise Line Holdings | Stephen G. Pagliuca | Dir | 1 giu 2026 | $18.11 | +$24,992,300 | >999% |
| 5 | IFF | Intl. Flavors & Fragrances | Paul J. Fribourg | Dir | 1 giu 2026 | $74.29 | +$20,317,855 | +11% |
| 6 | ARTV | Artiva Biotherapeutics, Inc. | GC Corp. | 10% | 11 mag 2026 | $11.52 | +$16,499,992 | +31% |
| 7 | QTTB | Q32 Bio Inc. | OrbiMed Advisors LLC | Dir, 10% | 28 mag 2026 | $8.00 | +$15,000,000 | — |
| 8 | QNT | Quantinuum Inc. | Hal Barron | Dir | 5 giu 2026 | $60.00 | +$15,000,000 | >999% |
| 9 | AXIA | Axia Energia S.A. | Pedro Batista De Lima Filho | Dir | 29 mag — 3 giu | ~$10.77 | +$13,786,862 | +36% |
| 10 | AUPH | Aurinia Pharmaceuticals Inc. | Kevin Tang | CEO, 10% | 29 mag 2026 | $15.29 | +$12,455,227 | +7% |
| 11 | WGS | GeneDx Holdings Corp. | Casdin Capital LLC | Dir, 10% | 4 giu 2026 | $55.55 | +$11,109,565 | +5% |
| 12 | FONR | Fonar Corp. | Hilary Shane | 10% | 27 mag — 2 giu | ~$19.05 | +$10,562,258 | +24% |
| 13 | HLNE | Hamilton Lane Inc. | Hartley R. Rogers | Exec Co-COB, 10% | 26 mag 2026 | $90.08 | +$9,992,338 | +2% |
| 14 | TXO | TXO Partners, L.P. | Bob R. Simpson | Dir, 10% | 27 mag — 2 giu | ~$13.65 | +$9,097,823 | +7% |
| 15 | COE | 51Talk Online Education Group | Jack Jiajia Huang | CEO, 10% | 22 mag — 29 mag | ~$25.74 | +$8,976,515 | 0% |
| 16 | NSP | Insperity, Inc. | Paul J. Sarvadi | COB, CEO | 3 giu 2026 | $34.05 | +$7,933,650 | +15% |
| 17 | MNSO | Miniso Group Holding Ltd. | Ye Guofu | CEO | 29 mag 2026 | $3.29 | +$6,901,010 | 0% |
| 18 | RDN | Radian Group Inc. | Michael S. Weinbach | CEO-Elect | 1 giu 2026 | $33.93 | +$5,768,292 | Nuovo |
| 19 | SLMT | Brera Holdings Plc | Keren Kalima Maimon | Dir, 10% | 21 mag 2026 | $4.97 | +$5,710,530 | +612% |
| 20 | OTLK | Outlook Therapeutics, Inc. | Ghiath M. Sukhtian | Dir, 10% | 28 mag 2026 | $0.59 | +$5,000,000 | +63% |
Fonte: SEC Form 4 filings via OpenInsider.com. Periodo: 27 maggio – 11 giugno 2026. Acquisti multipli dello stesso insider sullo stesso titolo sono aggregati. Sono esclusi i filing con prezzi a $0.00 (option exercises). Il ticker SVRE e’ stato escluso per errore di overflow nel database sorgente ($2.14B = INT32 max).
Chi ha comprato e perche’ conta
Di seguito i profili dei 10 acquisti piu’ rilevanti per dimensione, qualita’ dell’insider o contesto strategico.
LILA
Liberty Latin America Ltd. — Nasdaq
+$107M
Liberty Latin America e’ un operatore di telecomunicazioni (cavo, broadband, mobile) attivo nei Caraibi, in Cile e in America centrale. Controllata dal gruppo Liberty fondato da John Malone, opera sotto i brand VTR, C&W e Liberty Puerto Rico.
John C. Malone — Director Emeritus: il “cowboy del cavo”, fondatore e cervello del gruppo Liberty, ha acquistato 12,4 milioni di azioni a $8.63 il 22 maggio 2026, investendo $107 milioni e aumentando la sua quota del 96%. Un acquisto straordinario per dimensioni e aggressivita’. Malone e’ noto per comprare quando crede che il mercato stia sottovalutando il valore intrinseco dell’asset.
HOOD
Robinhood Markets, Inc. — Nasdaq
+$55M
Robinhood e’ la piattaforma di brokerage retail che ha democratizzato il trading senza commissioni. Negli ultimi anni ha diversificato con criptovalute, IRA, carte di credito e strumenti di risparmio. Il titolo e’ in forte uptrend nel 2026.
Malka Meyer — Direttore: ha acquistato $55,3 milioni in tre tranche tra il 28 maggio e il 5 giugno 2026, a prezzi tra $80.39 e $83.45 per azione. Tre acquisti in meno di due settimane sullo stesso titolo sono un segnale di alta convinzione. Nessuna opzione, nessun esercizio automatico: soldi veri al prezzo di mercato.
LFTO
Liftoff Mobile, Inc. — Nasdaq
+$30M
Liftoff Mobile e’ una piattaforma di mobile marketing e user acquisition per app. Opera con intelligenza artificiale per ottimizzare le campagne di acquisizione utenti per sviluppatori di app mobile. E’ recentemente approdata sui mercati pubblici.
General Atlantic — Dir, 10%: il noto fondo di private equity ha acquistato 1,3 milioni di azioni a $23.00 per $30M il 5 giugno 2026. L’acquisto da parte dello sponsor principale post-IPO, a prezzi di mercato aperto, e’ un segnale di continuata fiducia nel percorso di crescita dell’azienda.
NCLH
Norwegian Cruise Line Holdings — NYSE
+$25M
Norwegian Cruise Line e’ una delle grandi compagnie di crociere mondiali (brand NCL, Oceania Cruises, Regent Seven Seas). Opera con una flotta di oltre 30 navi e serve mercati globali. Il titolo e’ rimasto sotto pressione rispetto ai competitor nel 2025-2026.
Stephen G. Pagliuca — Direttore: co-proprietario dei Boston Celtics e managing director di Bain Capital, ha acquistato 1,38 milioni di azioni a $18.11 per circa $25 milioni il 1 giugno 2026. Il delta ownership e’ indicato come “>999%”, il che suggerisce che si tratta di un ingresso praticamente nuovo nella sua posizione su NCLH. Un segnale di forte convinzione da un investitore di profilo molto elevato.
IFF
International Flavors & Fragrances — NYSE
+$20M
IFF e’ uno dei maggiori produttori mondiali di aromi, fragranze e ingredienti funzionali per l’industria alimentare, cosmetica e farmaceutica. Dopo la fusione con DuPont Nutrition nel 2021, l’azienda ha attraversato una fase di ristrutturazione e riduzione del debito.
Paul J. Fribourg — Direttore: CEO di Continental Grain Company (una delle piu’ grandi aziende agricole private degli USA), ha acquistato 273.500 azioni di IFF a $74.29 per $20,3 milioni il 1 giugno 2026, aumentando la propria quota dell’11%. Un acquisto significativo da parte di un insider con grande esperienza nel settore alimentare e degli ingredienti.
ARTV
Artiva Biotherapeutics, Inc. — Nasdaq
+$16.5M
Artiva Biotherapeutics sviluppa terapie cellulari allogeniche basate su cellule NK (Natural Killer) per il trattamento di tumori ematologici e malattie autoimmuni. La piattaforma off-the-shelf permette di produrre terapie senza bisogno di cellule del paziente.
GC Corp. — azionista al 10%: GC Corp. (gia’ Green Cross Corp.) e’ uno dei principali gruppi farmaceutici e biotech della Corea del Sud. L’acquisto di 1,43 milioni di azioni a $11.52 per $16,5 milioni l’11 maggio 2026 aumenta la quota del 31% — un segnale di sostegno strategico significativo da parte del partner asiatico di Artiva.
QTTB
Q32 Bio Inc. — Nasdaq
+$15M
Q32 Bio e’ una societa’ biofarmaceutica focalizzata sulle patologie del sistema del complemento e delle malattie infiammatorie croniche. La pipeline include candidati per nefrite lupica e altre malattie autoimmuni rare.
OrbiMed Advisors LLC — Dir, 10%: OrbiMed e’ uno dei piu’ rispettati fondi specializzati in healthcare al mondo, con oltre $20 miliardi in gestione. Un acquisto diretto a $8.00 per azione da parte di OrbiMed — che gia’ siede nel board — e’ tra i segnali di insider buying piu’ credibili che si possano osservare in ambito biotech.
QNT
Quantinuum Inc. — NYSE
+$15M
Quantinuum e’ lo spin-off di Honeywell nel quantum computing, considerato uno dei leader mondiali nel settore con il processore H-Series. Opera sia nell’hardware (trap-ion qubits) sia nel software per applicazioni quantistiche in chimica, cybersecurity e ottimizzazione.
Hal Barron — Direttore: ex Chief Scientific Officer di GlaxoSmithKline e presidente di R&D di Alphabet, Barron e’ una figura di altissimo profilo scientifico e industriale. Il suo acquisto di $15 milioni a $60.00 il 5 giugno 2026 e’ praticamente un ingresso da zero (>999% delta), il che indica una decisione deliberata e convinta di prendere posizione in Quantinuum.
AUPH
Aurinia Pharmaceuticals Inc. — Nasdaq
+$12.5M
Aurinia Pharmaceuticals e’ una biofarmaceutica canadese. Ha ottenuto l’approvazione FDA per voclosporin (LUPKYNIS) per la nefrite lupica, ed e’ ora in fase di ridefinizione strategica e possibile M&A. E’ nota agli investitori come potenziale target di acquisizione.
Kevin Tang — CEO e 10% owner: Tang e’ un noto investitore attivista specializzato in biotech undervalued, con un track record rilevante. Il fatto che stia acquistando $12,5 milioni come CEO in carica — e gia’ azionista al 10% — suggerisce la sua visione di un valore non ancora riconosciuto dal mercato, oppure l’anticipazione di sviluppi societari positivi.
WGS
GeneDx Holdings Corp. — Nasdaq
+$11.1M
GeneDx e’ una delle principali aziende di sequenziamento genomico clinico negli USA, specializzata nella diagnosi di malattie rare nei bambini. Utilizza il whole genome sequencing (WGS) come strumento diagnostico di elezione per i casi complessi.
Casdin Capital LLC — Dir, 10%: Casdin Capital e’ un hedge fund specializzato in scienze della vita e tecnologia genomica. L’acquisto di $11,1 milioni a $55.55 il 4 giugno 2026 aumenta la quota del 5%, confermando la fiducia del fondo nella crescita di GeneDx nel mercato della diagnostica genomica pediatrica.
Pattern e segnali chiave
Guardando la lista complessiva, emergono alcune tendenze interessanti. Il biotech torna protagonista con ben tre presenze nelle prime dieci posizioni (ARTV, QTTB, AUPH), tutte con insider di alta qualita’ — un fondo come OrbiMed, un partner strategico come GC Corp., e un CEO-attivista come Kevin Tang. Il settore leisure/consumer e’ rappresentato da NCLH e LILA, entrambi con acquisti da board member di altissimo profilo e apparente forte convinzione sul value.
I pattern piu’ significativi da un punto di vista analitico sono: (1) gli acquisti multipli nello stesso titolo in poche settimane (HOOD, FONR, TXO), che suggeriscono una convinzione costruita nel tempo piuttosto che un acquisto una tantum; (2) gli ingressi da zero o quasi zero su titoli in cui l’insider non aveva posizione (NCLH, QNT, RDN), che indicano una scelta deliberata e non difensiva; (3) gli acquisti da azionisti al 10% che aumentano ancora la quota (ARTV, AUPH, OTLK), segnale tipico di chi crede in uno scenario di re-rating o M&A.
Ricorda: l’insider buying e’ un indicatore, non una certezza. Gli insider possono sbagliare, avere orizzonti temporali diversi dai tuoi, o comprare per motivi che non sono immediatamente visibili al mercato (es. accordi pre-esistenti, difesa da scalate, piani di acquisto programmati). Usalo come uno dei tanti strumenti di analisi, non come segnale d’azione automatica.
Disclaimer — Solo uso informativo ed educativo
Questo report e’ prodotto da Merlintrader a scopo esclusivamente informativo ed educativo. Non costituisce consulenza finanziaria, raccomandazione di investimento, sollecitazione all’acquisto o alla vendita di strumenti finanziari ai sensi del D.Lgs. 58/1998 (TUF) e della normativa CONSOB, ne’ ai sensi del Securities Act del 1933 o dell’Exchange Act del 1934 (SEC, USA).
I dati sugli acquisti insider sono estratti dai Form 4 depositati presso la SEC e aggregati tramite OpenInsider.com. Pur adoperando la massima cura nella verifica delle informazioni, Merlintrader non garantisce la completezza, l’accuratezza o la tempestivita’ dei dati. I prezzi di mercato, la situazione aziendale e le circostanze degli insider possono cambiare in qualsiasi momento.
Ogni decisione di investimento deve essere presa autonomamente dal lettore, preferibilmente con il supporto di un consulente finanziario autorizzato. Merlintrader non e’ responsabile per eventuali perdite derivanti dall’uso delle informazioni contenute in questo report.
Per il disclaimer completo: merlintrader.com/disclaimer/
When the big players put their money where their mouth is
Insider purchases — cash buys at market prices by those who know the company from the inside — are among the most closely watched signals by professional investors. They are not a guarantee, but when a CEO, a board member, or a 10% shareholder buys millions of dollars with their own money, something is worth examining.
Over the past two weeks (May 27 – June 11, 2026), we recorded 20 significant purchases with a combined value exceeding $462 million. The analysis excludes all options exercised at zero or symbolic prices: these are exclusively open-market purchases or direct offerings, paid at current stock market prices. Data sourced from Form 4 filings submitted to the SEC (Securities and Exchange Commission).
The strongest signal? John C. Malone investing $107 million in Liberty Latin America, nearly doubling his stake. Another notable signal: Malka Meyer purchasing Robinhood for $55 million across three separate tranches. Then Norwegian Cruise Line, IFF, two biotechs (Artiva and Q32 Bio), a quantum computing company (Quantinuum), and many others. Below is the complete list with key profiles.
Methodological note: this report excludes SVRE (Saverone 2014 Ltd.) — the recorded value of $2,147,483,647 corresponds to the maximum 32-bit integer and represents a database overflow error in the source, not a real purchase. All other data is consistent with the original SEC filings.
The full table — Top 20 purchases
Data updated as of June 11, 2026. Sorted by total purchase value, descending. Multiple purchases by the same insider in the same stock are consolidated.
| # | Ticker | Company | Insider | Role | Trade date | Avg. price | Total value | Delta % |
|---|---|---|---|---|---|---|---|---|
| 1 | LILA | Liberty Latin America Ltd. | John C. Malone | Director Emeritus | May 22, 2026 | $8.63 | +$107,067,776 | +96% |
| 2 | HOOD | Robinhood Markets, Inc. | Malka Meyer | Dir | May 28 — Jun 5 | ~$81.50 | +$55,306,259 | +3% |
| 3 | LFTO | Liftoff Mobile, Inc. | General Atlantic | Dir, 10% | Jun 5, 2026 | $23.00 | +$29,999,981 | +5% |
| 4 | NCLH | Norwegian Cruise Line Holdings | Stephen G. Pagliuca | Dir | Jun 1, 2026 | $18.11 | +$24,992,300 | >999% |
| 5 | IFF | Intl. Flavors & Fragrances | Paul J. Fribourg | Dir | Jun 1, 2026 | $74.29 | +$20,317,855 | +11% |
| 6 | ARTV | Artiva Biotherapeutics, Inc. | GC Corp. | 10% | May 11, 2026 | $11.52 | +$16,499,992 | +31% |
| 7 | QTTB | Q32 Bio Inc. | OrbiMed Advisors LLC | Dir, 10% | May 28, 2026 | $8.00 | +$15,000,000 | — |
| 8 | QNT | Quantinuum Inc. | Hal Barron | Dir | Jun 5, 2026 | $60.00 | +$15,000,000 | >999% |
| 9 | AXIA | Axia Energia S.A. | Pedro Batista De Lima Filho | Dir | May 29 — Jun 3 | ~$10.77 | +$13,786,862 | +36% |
| 10 | AUPH | Aurinia Pharmaceuticals Inc. | Kevin Tang | CEO, 10% | May 29, 2026 | $15.29 | +$12,455,227 | +7% |
| 11 | WGS | GeneDx Holdings Corp. | Casdin Capital LLC | Dir, 10% | Jun 4, 2026 | $55.55 | +$11,109,565 | +5% |
| 12 | FONR | Fonar Corp. | Hilary Shane | 10% | May 27 — Jun 2 | ~$19.05 | +$10,562,258 | +24% |
| 13 | HLNE | Hamilton Lane Inc. | Hartley R. Rogers | Exec Co-COB, 10% | May 26, 2026 | $90.08 | +$9,992,338 | +2% |
| 14 | TXO | TXO Partners, L.P. | Bob R. Simpson | Dir, 10% | May 27 — Jun 2 | ~$13.65 | +$9,097,823 | +7% |
| 15 | COE | 51Talk Online Education Group | Jack Jiajia Huang | CEO, 10% | May 22 — 29 | ~$25.74 | +$8,976,515 | 0% |
| 16 | NSP | Insperity, Inc. | Paul J. Sarvadi | COB, CEO | Jun 3, 2026 | $34.05 | +$7,933,650 | +15% |
| 17 | MNSO | Miniso Group Holding Ltd. | Ye Guofu | CEO | May 29, 2026 | $3.29 | +$6,901,010 | 0% |
| 18 | RDN | Radian Group Inc. | Michael S. Weinbach | CEO-Elect | Jun 1, 2026 | $33.93 | +$5,768,292 | New |
| 19 | SLMT | Brera Holdings Plc | Keren Kalima Maimon | Dir, 10% | May 21, 2026 | $4.97 | +$5,710,530 | +612% |
| 20 | OTLK | Outlook Therapeutics, Inc. | Ghiath M. Sukhtian | Dir, 10% | May 28, 2026 | $0.59 | +$5,000,000 | +63% |
Source: SEC Form 4 filings via OpenInsider.com. Period: May 27 – June 11, 2026. Multiple purchases by the same insider on the same stock are aggregated. Filings with $0.00 price (option exercises) are excluded. Ticker SVRE was excluded due to a database overflow error (INT32 max value of $2.14B).
Who bought and why it matters
Below are profiles of the 10 most relevant purchases by size, insider quality, or strategic context.
LILA
Liberty Latin America Ltd. — Nasdaq
+$107M
Liberty Latin America is a telecom operator (cable, broadband, mobile) active in the Caribbean, Chile, and Central America. Controlled by the Liberty group founded by John Malone, it operates under the VTR, C&W, and Liberty Puerto Rico brands.
John C. Malone — Director Emeritus: the “cable cowboy,” founder and strategic mind behind the Liberty group, purchased 12.4 million shares at $8.63 on May 22, 2026, investing $107 million and increasing his stake by 96%. An extraordinary purchase in both size and aggressiveness. Malone is known for buying when he believes the market is undervaluing an asset’s intrinsic worth.
HOOD
Robinhood Markets, Inc. — Nasdaq
+$55M
Robinhood is the commission-free retail brokerage platform that democratized trading. In recent years it has diversified into crypto, IRAs, credit cards, and savings tools. The stock has been in a strong uptrend in 2026.
Malka Meyer — Director: purchased $55.3M across three tranches between May 28 and June 5, 2026, at prices between $80.39 and $83.45 per share. Three purchases in under two weeks on the same stock is a high-conviction signal. No options, no automatic exercise: real money at market price.
NCLH
Norwegian Cruise Line Holdings — NYSE
+$25M
Norwegian Cruise Line is one of the world’s major cruise companies (NCL, Oceania Cruises, Regent Seven Seas brands). It operates a fleet of over 30 ships serving global markets. The stock has remained under pressure versus competitors in 2025-2026.
Stephen G. Pagliuca — Director: co-owner of the Boston Celtics and managing director at Bain Capital, purchased 1.38 million shares at $18.11 for ~$25M on June 1, 2026. The ownership delta is listed as “>999%”, suggesting this is essentially a new position in NCLH. A strong conviction signal from a very high-profile investor.
IFF
Intl. Flavors & Fragrances — NYSE
+$20M
IFF is one of the world’s largest producers of flavors, fragrances, and functional ingredients for the food, cosmetics, and pharmaceutical industries. After merging with DuPont Nutrition in 2021, the company has been restructuring and reducing debt.
Paul J. Fribourg — Director: CEO of Continental Grain Company (one of the largest private agricultural firms in the US), purchased 273,500 IFF shares at $74.29 for $20.3M on June 1, 2026, increasing his stake by 11%. A significant purchase from an insider with deep expertise in food and ingredients.
ARTV
Artiva Biotherapeutics — Nasdaq
+$16.5M
Artiva Biotherapeutics develops allogeneic cell therapies based on NK (Natural Killer) cells for hematologic tumors and autoimmune diseases. The off-the-shelf platform allows therapies to be produced without requiring the patient’s own cells.
GC Corp. — 10% shareholder: GC Corp. (formerly Green Cross Corp.) is one of South Korea’s leading pharma and biotech groups. The purchase of 1.43M shares at $11.52 for $16.5M on May 11, 2026 increases their stake by 31% — a significant strategic support signal from Artiva’s Asian partner.
QTTB
Q32 Bio Inc. — Nasdaq
+$15M
Q32 Bio is a biopharmaceutical company focused on complement system disorders and chronic inflammatory diseases. Its pipeline includes candidates for lupus nephritis and other rare autoimmune conditions.
OrbiMed Advisors LLC — Dir, 10%: OrbiMed is one of the most respected global healthcare-focused investment funds, with over $20 billion under management. A direct open-market purchase at $8.00/share by OrbiMed — which already sits on the board — is among the most credible insider buying signals observable in biotech.
QNT
Quantinuum Inc. — NYSE
+$15M
Quantinuum is Honeywell’s quantum computing spin-off, considered one of the global leaders in the sector with its H-Series processor. It operates in both hardware (trapped-ion qubits) and software for quantum applications in chemistry, cybersecurity, and optimization.
Hal Barron — Director: former Chief Scientific Officer at GlaxoSmithKline and R&D president at Alphabet, Barron is a figure of the highest scientific and industrial stature. His $15M purchase at $60.00 on June 5, 2026 is essentially a new entry (>999% delta), indicating a deliberate and high-conviction decision to take a position in Quantinuum.
AUPH
Aurinia Pharmaceuticals — Nasdaq
+$12.5M
Aurinia Pharmaceuticals is a Canadian biopharma. It received FDA approval for voclosporin (LUPKYNIS) for lupus nephritis and is now in strategic redefinition and possible M&A phase. It is known to investors as a potential acquisition target.
Kevin Tang — CEO and 10% owner: Tang is a well-known activist investor specializing in undervalued biotech, with a notable track record. Purchasing $12.5M as the sitting CEO — and already a 10% shareholder — suggests his view of unrecognized value, or anticipation of positive corporate developments.
WGS
GeneDx Holdings Corp. — Nasdaq
+$11.1M
GeneDx is one of the leading clinical genomic sequencing companies in the US, specializing in diagnosing rare diseases in children. It uses whole genome sequencing (WGS) as the primary diagnostic tool for complex cases.
Casdin Capital LLC — Dir, 10%: Casdin Capital is a hedge fund specializing in life sciences and genomic technology. The purchase of $11.1M at $55.55 on June 4, 2026, increasing their stake by 5%, reinforces the fund’s confidence in GeneDx’s growth in the pediatric genomic diagnostics market.
NSP
Insperity, Inc. — NYSE
+$7.9M
Insperity is a professional employer organization (PEO) providing HR, payroll, benefits, and employee management services to small and mid-size businesses in the US. It is one of the largest PEOs in the country.
Paul J. Sarvadi — COB and CEO: founder of Insperity, Sarvadi purchased $7.9M worth of shares at $34.05 on June 3, 2026, raising his stake by 15%. A founder-CEO buying in the open market at scale is a historically meaningful signal of conviction in the company’s near-term outlook.
Key patterns and signals
Looking at the overall list, a few trends stand out. Biotech returns as a protagonist with three of the top ten slots (ARTV, QTTB, AUPH), all featuring high-quality insiders — a fund like OrbiMed, a strategic partner like GC Corp., and an activist-CEO like Kevin Tang. Leisure/consumer is represented by NCLH and LILA, both with purchases from very high-profile board members showing apparent strong conviction around value.
The most analytically significant patterns are: (1) multiple purchases in the same stock within weeks (HOOD, FONR, TXO) — suggesting conviction built over time rather than a one-off; (2) entries from near-zero positions in stocks where the insider had no prior holding (NCLH, QNT, RDN) — indicating a deliberate rather than defensive choice; (3) purchases by 10%+ shareholders increasing their already large stakes (ARTV, AUPH, OTLK) — a typical signal ahead of a re-rating or M&A event.
Remember: insider buying is an indicator, not a certainty. Insiders can be wrong, have different time horizons than you, or buy for reasons not immediately visible to the market (e.g., pre-existing agreements, takeover defense, pre-programmed purchase plans). Use it as one of many analytical tools, not as an automatic action trigger.
Disclaimer — Educational and informational use only
This report is produced by Merlintrader for exclusively informational and educational purposes. It does not constitute financial advice, an investment recommendation, or a solicitation to buy or sell financial instruments under Italian law (D.Lgs. 58/1998, TUF and CONSOB regulations) or US law (Securities Act of 1933 or Exchange Act of 1934, SEC).
Insider purchase data is extracted from Form 4 filings submitted to the SEC and aggregated via OpenInsider.com. While every care has been taken to verify the information, Merlintrader does not guarantee the completeness, accuracy, or timeliness of the data. Market prices, company situations, and insider circumstances may change at any time.
Any investment decision must be made independently by the reader, preferably with the support of a licensed financial advisor. Merlintrader is not responsible for any losses arising from the use of information in this report.
Full disclaimer: merlintrader.com/disclaimer/
Biotech & Tech Catalyst Calendar
Track upcoming catalysts: FDA PDUFA dates, clinical readouts, earnings and market events on Merlintrader. Updated regularly.
Go to the Catalyst CalendarBiotech & Tech Catalyst Calendar
Segui i prossimi catalyst: PDUFA FDA, readout clinici, earnings ed eventi di mercato su Merlintrader. Aggiornato regolarmente.
Vai al Catalyst CalendarScanner for active traders
Try ChartsWatcher free, then unlock 10% OFF with SAVE10
ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.
Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.
Start free – then use SAVE10
No credit card required to start. Apply SAVE10 when upgrading.
Recommended platform
One platform. All your brokers.
Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.
A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.
Get 1 Month Free ➔
Multi-broker workflow + customizable layouts in one platform.
Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site
Find out how I use AI on Merlintrader: AI, retail and Merlintrader
Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.
